We hope that all of you are doing fine despite this exceptional COVID-19 situation. We have decided to postpone the CSBC conference to next year. The conference will be arranged at the same place (Spa hotel Rauhalahti, Kuopio) from Wednesday 9th of June to Friday 11th of June 2021. We really hope that you are able to attend the conference despite the changed date.
If you have already registered, the registration is automatically valid for the next year’s conference but if you prefer cancelling the registration, we will return the participation fee to your account. All the registered attendees are contacted via e-mail. If you have registered but haven’t been contacted do not hesitate to contact us at firstname.lastname@example.org.
These web-pages will be updated about the upcoming event!
On behalf of the organizing committee,
Juri Timonen & Tuulia Tynkkynen
Dr. Petri Turhanen, Ph.D, is university
researcher at University of Eastern Finland (UEF), School of Pharmacy. He
received M.Sc. in organic chemistry at University of Jyväskylä in 1997 and
Ph.D. in synthetic organic and medicinal chemistry at University of Kuopio in
2003. His scientific interests are focused on synthetic
chemistry with green chemistry aspect and on organophosphorus chemistry (like bisphosphonates
and ATP analogues) and novel applications of prepared compounds. Dr. Turhanen has authored more than 50 publications
and conference presentations being a main author in most of them, he also has 2
Dr. Turhanen is currently acting as Guest Associate Editor in Frontiers
in Chemistry in Research Topic: “Phosphonate
Chemistry in Drug Design and Development” and Guest Editor in Sustainability special issue: “Synthesis Methods with Green Chemistry
Aspect”. He is also Editorial board member of Current Medicinal Chemistry.
Katja Petzold was born in Dresden, Eastern Germany, in 1981. She obtained her Biochemistry/Biotechnology degree in protein folding from the Martin-Luther University Halle, Germany in 2005. Thereafter, she received her Ph.D. in Medical Biophysics from Umeå University,Sweden in 2009 working with Prof. J. Schleucher, where she started her work on NMR method development for nucleic acids as well as for phospholipids. She then spent a short time as researcher at the University of KwaZulu/Natal, Durban, South Africa learning about small molecule drug design while establishing advanced small molecule NMR. After that she completed a postdoctoral fellowship with H.M. Al-Hashimi at University of Michigan, Ann Arbor, studying RNA dynamics and the structure of RNA excited states, resulting in two Nature publications. In 2014, she moved to the Karolinska Institute, Stockholm, Sweden, where she is currently an Associate Professor of Biophysics. She has received a number of prizes, e.g. the Ampere prize of the NMR society and the Wallenberg Academy Fellow and secured prestigious funding. Her group’s research focuses on the study of RNA dynamics of disease related systems, such as ribosomes or microRNA (latest Nature publication), including viruses. The group works both on method development for NMR and RNA biophysics as well as identifying regulatory mechanism in RNA based on structural changes, so called excited states.
Federation of European Biological Societies (FEBS) has nominated Professor Finnbar O’Harte (Ulster University, UK) as a recipient of FEBS National Lecture award. The award will be presented at Chemical Sciences in Biological Challenges Symposium at Kuopio, Finland, June 3-5, 2020. Professor O’Harte has made fundamental contributions in development of stable peptide analogues for therapy of Type 2 diabetes and obesity. In the symposium he will deliver a talk “Apelin-13 peptide analogues versus incretin mimetics for alleviating metabolic dysfunction in diabetes: A comparative study”
Bernd W.K. Diehl was born in 1960. He
completed his studies (Dr. rer. Nat Dipl. Chemist) in Organic chemistry and NMR
spectroscopy at Philipps University Marburg in 1988.
Bernd has worked at Bayer Research Center
(1988-1990) as a head of NMR spectroscopy and he is a founder and CEO of
Spectral Service AG (since 1990) at Cologne Germany. Bernd is also a founder of
Steelyard Analytics Inc. (founded 2017) that is located at Manassas, the USA.
During working on the industry, Bernd has had professorships in University of
Marburg and Bonn (NMR spectroscopy, 1998-2000), University of Applied Science
Bonn-Rhein-Sieg (NMR spectroscopy, since 2013) and University of Würzburg (mass
spectrometry, 2015-2019), as well as guest professorship in Loyola University
Chicago in 2017.
Bernd has received the title of an honorary
professor from the Hochschule Bonn-Rhein Sieg (HBRS) for his efforts on lecturing
and work on the field of chemical industry for 30-years. He is also president
of I.L.P.S. (International Lecithin and Phospholipid Society).
Prof. Bernd Diehl has been involved in
developing and publishing over 50 NMR methods for analyzing food products,
pharmaceuticals and chemicals. Within last years he has also supported in total
eight degree theses at HBRS and Spectral Service AG.
Arri Priimägi was born in 1980 in Tallin, Estonia. He graduated in 2004 as a Master of Science and Technologu from the Tampere University of Technology and moved to the Helsinki University of Technology for carrying ot his doctoral studies.
After Priimägi got his PhD in 2009 from the Helsinki Univiersity of Technology he worked as a post-doc in Aalto University and moved in 2010 to Tokyo Institute of Technology (Japan). During the two years in Japan, Priimägi continued his work with photoreactive materials. After returning for one more year in Aalto university, he moved to Department of Chemistry, Materials, and Chemical Engineering, Politecnico di Milano, Italy.
In 2014 Priimägi started his tenure-track as an assistant professor in Tampere University of Technology, and turned three years later into associate professor and finally in 2019 to a full professor.
Professor Priimägi is intrigued by functional soft materials whose properties can be controlled by external stimuli. The main reasons are the scientific curiosity, and the belief that the disruptive technologies of tomorrow are ultimately driven by the development of advanced and creative materials concepts.
For more, please visit: https://www.tuni.fi/en/arri-priimagi
Kostas Demadis was born in Komotini (Thrace, Northern Greece) in 1967. He received his Bachelors Degree from the University of Athens in 1990 and his Ph.D. in Chemistry at the University of Michigan, USA in 1995. He then moved to the University of North Carolina, Chapel Hill (UNC) for a post-doc. In 1998, he was hired by Nalco Chemical Company as a Senior Chemist in their R & D Division.
Kostas is a Full
Professor in the Department of Chemistry, University of Crete, and Head of the
Crystal Engineering, Growth & Design Laboratory.
group is interested in a number of research areas: Coordination polymers with
emphasis on metal phosphonate MOFs, functional polymers, silicon chemistry
(modeling of biosilicification mechanisms), water treatment issues (mineral
scale inhibition, corrosion control, metal ion absorption), controlled delivery/release
of active pharmaceutical ingredients (in particular bisphosphonate drugs), “green”
chemistry, and hybrid polymeric materials for Cultural Heritage protection.
Professor Demadis has
published ~180 papers in peer-reviewed journals, about two dozen chapters in
books, four books, and is the inventor of two patents.
Paweł Kafarski was born in 1949. He studied chemistry at Wrocław University of Science and Technology where his scientific adventure started with M. Sc. Thesis, completed in 1971, followed by doctoral thesis (1977) both under the supervision of Prof. Przemysław Mastalerz. Prof. Mastalerz subsequently supervised his scientific career for many years. In his laboratory Paweł Kafarski worked on the synthesis of organophosphorus compounds and their potential biological activities. In 1976/1977 he interrupted his PhD studies and spent nine months at Marquette University at Milwaukee working in the laboratory of Prof. Sheldon E. Cremer on the synthesis of phosphetanes. In 1989 he spent six months in the laboratory of Prof. Henri-Jean Cristau at Ecole Nationale Superieure de Chimie at Montpellier elaborating the procedure for the synthesis of phosphono peptides containing P-N bond in their structures. Scientific activity of Paweł Kafarski was concentrated on elaboration of synthetic procedures suitable to produce phosphonate inhibitors (most likely in enantiomerically pure forms) of physiologically important enzymes, to mention only: aminopeptidases (targets for anti-cancer and anti-malarial drugs), cathepsin C (potential anti-tumor agents), glutamine synthetase (target for ant-tuberculosis agents), urease (antibacterials for treatment of stomach ulcer and stone formation in urinary tract) or L-phenylalanine ammonia lyase (potential herbicides). The design of ligands for these targets relied on knowledge of molecular mechanisms of the catalyzed reactions and on three-dimensional structures of the chosen proteins. He coauthored over 350 papers, which are well cited in the literature (over 5500 independent citations).
Finbarr O’Harte completed his BSc Hons. degree in Biochemistry in 1986 and his PhD in Clinical Biochemistry (Veterinary Sciences Department), at Queen’s University Belfast in 1989. He worked in regulatory peptide research at Creighton University Medical School in Omaha, Nebraska, USA (1989-91), followed by a post-doctoral position in Biochemistry at University College Cork (1992-93). He has been involved in diabetes research since moving to the Ulster University at Coleraine in 1993 as a Post-Doctoral fellow. He took up an academic appointment at Ulster University in 1995. He was promoted to Reader in 2000 and to a Professor in 2005. He is currently a Professor of Endocrinology & Metabolism within the school of Biomedical Sciences at the Coleraine campus. He has supervised numerous MSc and MRes level students and 20 PhD students.
His research interests have focused on drug discovery and development of stable peptide analogues for therapy of Type 2 diabetes and obesity. He has attracted significant research funding and has worked with numerous peptides including GIP, GLP-1, glucagon antagonists, CCK and apelin-13. He has designed stable bioactive peptide analogues, which have been tested in cultured cells and in vivo in acute and chronic small animal studies. This work produced to a number of research discoveries, leading to development of a strong intellectual property and patent portfolio. He is an academic co-founder of Diabetica Limited, an Ulster University start-up company focused on innovative diabetes peptide therapeutics.
He has over 130 full peer-reviewed publications (h-index 37) with many presentations at national and international conferences and was recipient of the Nordisk Medal of the Irish Endocrine Society (2005). He has recently held the position of the President of the Irish Endocrine Society 2015-2018.